Re: Letter Agreement dated as of June 15, 2004 by and between Noven Pharmaceuticals, Inc. (“Noven”) and Shire US Inc. (“Shire US”) relating to the development of an Amphetamine Transdermal Delivery System (the “2004 Letter Agreement”), such agreement...Noven Pharmaceuticals Inc • August 8th, 2007 • Pharmaceutical preparations
Whereas the parties have been engaged in the development of an Amphetamine Transdermal Delivery System (the “Product”) under the terms of the ATS Agreement, and
Re: Letter Agreement dated as of June 15, 2004 by and between Noven Pharmaceuticals, Inc. (“Noven”) and Shire US Inc. (“Shire US”) relating to the Development of the Amphetamine Transdermal Delivery System (the “Agreement”)Letter Agreement • August 8th, 2007 • Noven Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This letter agreement (the “Amendment”) supplements and amends the Agreement between Noven and Shire US relating to the development of an amphetamine transdermal delivery system (the “Product”), such Agreement having been assigned by Shire US to and assumed by its affiliate Shire Pharmaceuticals Ireland Limited (“Shire Ireland” and, together with Shire US, “Shire”) pursuant to its terms and that certain Assignment and Assumption Agreement between Shire US and Shire Ireland dated as of May 25, 2006. This Amendment supersedes and replaces the letter agreement between the parties dated July 20, 2006.
